Randomized Phase 3 Trial Comparing Combined Hepatic Arterial Infusion Pump and Systemic Therapy
Versus Systemic Therapy Alone for Unresectable Colorectal Liver Metastases
Led by The Netherlands Cancer Institute · Updated on 2025-03-04
306
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a treatment approach for patients with colorectal cancer that has spread to the liver but cannot be surgically removed. This clinical trial compares the combined use of Hepatic Arterial Infusion Pump therapy and systemic chemotherapy against systemic chemotherapy alone to see if the combination improves survival. The study focuses on patients who have not received prior chemotherapy and do not have cancer outside the liver.
Participants in the experimental group undergo surgery to implant a pump that delivers the chemotherapy drug Floxuridine directly to the liver, along with systemic chemotherapy given intravenously. The pump treatment cycles last four weeks, while systemic therapies such as FOLFOX or FOLFIRI are administered every two weeks. The control group receives standard systemic chemotherapy without the pump. Both groups have their tumor operability assessed by a specialized liver panel and complete quality of life questionnaires.
Throughout the study, patients will have imaging scans including CT angiography and specialized scintigraphy to monitor treatment effects. Researchers will track overall survival for up to five years, along with secondary outcomes like progression-free survival, response rates, surgical complications, and quality of life. Safety and side effects of the therapies are carefully recorded. The total participation time may last several years with regular follow-up visits and evaluations.
CONDITIONS
Brief Title
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
Research Team
K
Koert FD Kuhlmann, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Unresectable synchronous colorectal liver metastases confirmed by National Liver Panel
No extrahepatic metastases, except small lesions (10 mm or less) not clearly suspicious
No prior systemic therapy for colorectal cancer
Catheter placement feasible for hepatic arterial infusion pump
ECOG performance status 0 or 1
Life expectancy at least 12 weeks
Known RAS and BRAFV600E mutation status
Primary tumor in place and resectable without neoadjuvant therapy
Eligible for surgery and doublet chemotherapy
Adequate bone marrow, liver, and kidney function based on laboratory tests
Written informed consent given according to regulations
You will not qualify if you...
Prior hepatic radiation, surgery, or ablation
Any malignancy or condition interfering with treatment or prognosis, per physician
History of prior malignancy except certain low-risk or treated cancers without active disease for 3 years
Obstructive primary tumor requiring emergency surgery or extensive resection
Mismatch repair deficiency
DPD deficiency
Pregnant or breastfeeding women
Serious systemic disorders compromising safety or study completion
Organ transplant recipients on immunosuppressive therapy
Serious non-healing wounds, ulcers, or bone fractures
Chronic corticosteroid treatment at doses 10 mg/day or higher
Known serious infections uncontrolled or requiring treatment
Significant psychiatric disability affecting consent or compliance
Conditions hampering study compliance or follow-up
Underlying liver disease including fibrosis or cirrhosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - 1 day for surgery plus up to 2 weeks for immediate post-operative care
Participants in the experimental arm undergo surgery to implant the hepatic arterial infusion pump and resect the primary tumor before starting induction treatment.
1 surgical visit and post-operative monitoring visits
Treatment
Duration - Up to 6 months of induction treatment
Participants receive induction treatment. Those in the experimental arm receive floxuridine via the hepatic arterial infusion pump every 4 weeks combined with systemic therapy (FOLFOX or FOLFIRI) every 2 weeks. Participants in the control arm receive systemic therapy alone (CAPOX every 3 weeks or FOLFOX/FOLFIRI/FOLFOXIRI every 2 weeks) with optional bevacizumab.
Systemic therapy visits every 2 to 3 weeks; pump therapy every 4 weeks for experimental arm
Follow-up
Duration - Up to 5 years
Participants are monitored for long-term outcomes including survival, disease progression, quality of life, and adverse events up to five years after randomization.
Periodic follow-up visits according to clinical practice
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Registry Evaluating Safety and Performance of Teleflex Vascular Access Devices
in Real-World Medical Use
Open-Label Study Evaluating BLU-924 Safety and Activity in Advanced Pancreatic, Lung, and Colorectal Cancers with KRAS Mutations
Evaluation of a Web-Based Decision Support Tool for Detecting Invasive Cancer in Large Colorectal Polyps During Colonoscopy
Study of a New Oral Synbiotic Formula to Lower Advanced Adenoma Recurrence and Related Bacterial Markers After Colorectal Neoplasia Removal
Phase III Study of UCB4594, a Monoclonal Antibody Targeting HLA-G, Alone and With Other Cancer Treatments in Adults With Advanced Solid Tumors
Phase 3 Study Comparing FOLFIRI With or Without Bevacizumab to Irinotecan With or Without Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer
Randomized Study Comparing Amivantamab Plus FOLFIRI Versus Cetuximab or Bevacizumab Plus FOLFIRI in Adults With KRASNRAS and BRAF Wild-type Recurrent or Metastatic Colorectal Cancer After Prior Chemotherapy
Randomized Study Comparing Amivantamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy for First-line Treatment of KRASNRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of DM002 Drug for Adults With Advanced Solid Tumors Using Increasing Doses to Find the Best Treatment Level
Phase 1 Study of JNJ-89402638 Alone and with Bevacizumab or Chemotherapy for Metastatic Colorectal and Gastric Cancers
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT.